#USA #Rochester #Contact Lenses #CooperVision #NCC 2026

Overview of CooperVision's Research at NCC 2026

CooperVision, a leader in the contact lens industry, will showcase a series of scientific articles and posters at the upcoming 2026 Netherlands Contact Lens Congress (NCC), scheduled for March 8-9 in Veldhoven, Netherlands. This event is part of the British Contact Lens Association's scientific session, emphasizing the significance of evidence-based care and continuous innovation in enhancing the comfort and transparency of contact lenses throughout different life stages.

During the conference, Marcella McParland, an esteemed figure in the field and the Senior Director of Professional Affairs for EMEA at CooperVision, expressed the company's dedication to improving everyday vision. She stated, "Our commitment involves developing advanced contact lens designs and modalities that evolve according to users' vision needs." This statement highlights how CooperVision's findings can help eye care professionals effectively guide patients from their initial experience with contact lenses to managing issues associated with presbyopia.

Key Research Highlights

The research being presented is compelling, with a specific study indicating a smooth transition from single vision to dual-focal design lenses, such as MiSight® 1 day, aimed at myopia control. This particular transition showed that young adults experienced similar levels of visual quality and comfort within just six months of changing lens types. This finding underlines the importance of managing patient expectations about comfort and visual quality during the adjustment period.*

Further validating CooperVision's products, another piece of research emphasizes that modern spherical contact lens designs, including MyDay®, Biofinity®, and Biofinity Energys®, continue to meet the daily needs of both new and experienced lens wearers regarding comfort, vision, and overall performance. Additionally, the posters to be featured will delve into the perspectives of practitioners and users on remote eye care, exploring the reasons behind and decision-making processes of both new and veteran contact lens wearers. These discussions reveal specific opportunities for trial and adoption.

Research on Multifocal Lenses

As patients progress along the continuum of lens wear up to presbyopia, CooperVision’s research presented at the NCC also includes three studies focusing on multifocal contact lenses. One study suggests proactive adaptation strategies for early presbyopic patients and a closer alignment with fitting guide recommendations. Other studies illustrate encouraging satisfaction rates among wearers of hydrogel multifocal lenses transitioning to silicone hydrogel materials, alongside positive feedback from both new and habitual lens users trying multifocal contacts for the first time.

For those interested in further reading, detailed information on these studies can be found in the Abstracts 2026 - Nederlands Contactlens Congres. Organized every two years, the NCC gathers thousands of eye care professionals, educators, researchers, and manufacturers from the Netherlands, Europe, and beyond, highlighting the collaborative efforts and innovations within the field.

About CooperVision

CooperVision, a division of CooperCompanies (Nasdaq COO), stands as one of the world's leading manufacturers of contact lenses. The company offers a comprehensive range of daily, bi-weekly, and monthly soft contact lenses, incorporating advanced materials and optics, as well as top-quality gas permeable lenses for ortho-k and scleral designs. With a strong focus on addressing complex vision issues like astigmatism, presbyopia, childhood myopia, and highly irregular corneas, CooperVision provides the most extensive lineup of spherical, toric, and multifocal products available today. By combining innovative offerings with targeted support for practitioners, CooperVision delivers a refreshing perspective in the market, yielding real benefits for clients and wearers alike.

About CooperCompanies

CooperCompanies (Nasdaq COO) is a leading global medical device company dedicated to helping people live their best life moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, continually striving to improve everyday vision. Meanwhile, CooperSurgical champions fertility and women's healthcare, aiming to support women, babies, and families during pivotal health moments. With its headquarters in San Ramon, California, CooperCompanies employs over 15,000 people, sells products in more than 130 countries, and positively impacts over 50 million lives every year.

For more information, please visit coopervision.com and coopercos.com.